User login
C-reactive protein (CRP) is an independent predictor of a first cardiovascular event in women and appears to be a stronger predictor than low-density lipoprotein (LDL) cholesterol levels.
Unfortunately, this information does not lead directly to a therapeutic intervention. As an accompanying editorial stated, low carotenoid levels also predict cardiovascular events, but supplementation with beta carotene does not reduce an individual’s risk.1
This study does not clarify whether CRP is a causative agent, a marker, or a result of cardiovascular disease. Our focus should remain on identifying and treating conventional risk factors until we better understand the exact role CRP has in therapeutic decisions regarding cardiovascular disease.
C-reactive protein (CRP) is an independent predictor of a first cardiovascular event in women and appears to be a stronger predictor than low-density lipoprotein (LDL) cholesterol levels.
Unfortunately, this information does not lead directly to a therapeutic intervention. As an accompanying editorial stated, low carotenoid levels also predict cardiovascular events, but supplementation with beta carotene does not reduce an individual’s risk.1
This study does not clarify whether CRP is a causative agent, a marker, or a result of cardiovascular disease. Our focus should remain on identifying and treating conventional risk factors until we better understand the exact role CRP has in therapeutic decisions regarding cardiovascular disease.
C-reactive protein (CRP) is an independent predictor of a first cardiovascular event in women and appears to be a stronger predictor than low-density lipoprotein (LDL) cholesterol levels.
Unfortunately, this information does not lead directly to a therapeutic intervention. As an accompanying editorial stated, low carotenoid levels also predict cardiovascular events, but supplementation with beta carotene does not reduce an individual’s risk.1
This study does not clarify whether CRP is a causative agent, a marker, or a result of cardiovascular disease. Our focus should remain on identifying and treating conventional risk factors until we better understand the exact role CRP has in therapeutic decisions regarding cardiovascular disease.